Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia and End‐Stage Renal Disease Receiving Intermittent Hemodialysis

ASPECT‐NP, a phase 3 trial of ceftolozane/tazobactam in hospital‐acquired/ventilator‐associated bacterial pneumonia (HABP/VABP), excluded patients with end‐stage renal disease (ESRD). A modeling/simulation approach was undertaken to inform optimal dosing in this population, using previously develope...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Hwa‐Ping, Patel, Yogesh T., Zhang, Zufei, Fiedler‐Kelly, Jill, Bruno, Christopher J., Rhee, Elizabeth G., De Anda, Carisa, Gao, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Continuing Education: Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092127/
https://www.ncbi.nlm.nih.gov/pubmed/36046982
http://dx.doi.org/10.1002/jcph.2149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092127/
https://www.ncbi.nlm.nih.gov/pubmed/36046982
http://dx.doi.org/10.1002/jcph.2149

Ejemplares similares